Dual and multi-agonist synthetic peptides at the GLP-1 and glucagon receptor are currently in clinical development as potential new treatments for T2D and other chronic metabolic conditions including obesity, chronic kidney disease and metabolic dysfunction-associated steatohepatitis16–19. This evidence concerns the gene GCG and type 2 diabetes mellitus.